Herein, we show a selective action of WIN 55-212.2 mesylate, a synthetic cannabinoid with affinity for CB1 and CB2 higher than THC, on prostate cancer cell lines without affecting healthy counterpart. Here, CNR2 is linked to prostate cancer.